CN101405298A - 垂体腺苷酸环化酶激活肽(pacap)受体(vpac2)激动剂及其药物使用方法 - Google Patents

垂体腺苷酸环化酶激活肽(pacap)受体(vpac2)激动剂及其药物使用方法 Download PDF

Info

Publication number
CN101405298A
CN101405298A CNA038166445A CN03816644A CN101405298A CN 101405298 A CN101405298 A CN 101405298A CN A038166445 A CNA038166445 A CN A038166445A CN 03816644 A CN03816644 A CN 03816644A CN 101405298 A CN101405298 A CN 101405298A
Authority
CN
China
Prior art keywords
polypeptide
lys
diabetes
people
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038166445A
Other languages
English (en)
Chinese (zh)
Inventor
W·A·弗罗兰德
D·N·克尔纳
M·L·杜马斯
潘晓群
J·惠兰
王有章
王炜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of CN101405298A publication Critical patent/CN101405298A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
CNA038166445A 2002-07-12 2003-07-11 垂体腺苷酸环化酶激活肽(pacap)受体(vpac2)激动剂及其药物使用方法 Pending CN101405298A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39573802P 2002-07-12 2002-07-12
US60/395,738 2002-07-12

Publications (1)

Publication Number Publication Date
CN101405298A true CN101405298A (zh) 2009-04-08

Family

ID=30115918

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038166445A Pending CN101405298A (zh) 2002-07-12 2003-07-11 垂体腺苷酸环化酶激活肽(pacap)受体(vpac2)激动剂及其药物使用方法

Country Status (20)

Country Link
US (2) US7378494B2 (enExample)
EP (1) EP1578358A2 (enExample)
JP (1) JP2006506969A (enExample)
CN (1) CN101405298A (enExample)
AR (1) AR040548A1 (enExample)
AU (1) AU2003267990A1 (enExample)
BR (1) BR0312621A (enExample)
CA (1) CA2491279A1 (enExample)
DO (1) DOP2003000669A (enExample)
GT (1) GT200300142A (enExample)
HN (1) HN2003000217A (enExample)
IL (1) IL165499A (enExample)
MX (1) MXPA04012305A (enExample)
PE (1) PE20040677A1 (enExample)
PL (1) PL377025A1 (enExample)
RU (1) RU2360922C2 (enExample)
TW (1) TW200409641A (enExample)
UY (1) UY27893A1 (enExample)
WO (1) WO2004006839A2 (enExample)
ZA (1) ZA200501118B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794217A (zh) * 2014-08-06 2017-05-31 血管生物科学 包含对患病组织具有选择性的药效团的组合物及其制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
EP1713493A4 (en) * 2004-01-27 2009-06-24 Bayer Pharmaceuticals Corp PEPTIDE-RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND PHARMACOLOGICAL METHODS OF USING THESE AGONISTS
US20080096811A1 (en) * 2004-05-21 2008-04-24 Eli Lilly And Company Selective vpac2 receptor peptide agonists
CA2564740A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
WO2005119524A2 (en) 2004-06-04 2005-12-15 Therasense, Inc. Diabetes care host-client architecture and data management system
EP1768686A4 (en) * 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
CA2577010A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
US7595294B2 (en) 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20070293429A1 (en) * 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
WO2006042152A2 (en) 2004-10-08 2006-04-20 Forbes Medi-Tech (Research) Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20080214440A1 (en) * 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US20060159737A1 (en) * 2004-11-19 2006-07-20 Steffen Panzner Pharmaceutical compositions for local administration
ATE432322T1 (de) * 2004-12-21 2009-06-15 Lubrizol Ltd Zusammensetzungen
WO2006110551A2 (en) * 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
EP1896048A4 (en) * 2005-05-06 2010-11-03 Bayer Pharmaceuticals Corp PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
EP1915393A1 (en) * 2005-08-11 2008-04-30 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US7582608B2 (en) * 2005-10-26 2009-09-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
BRPI0708341A2 (pt) * 2006-02-28 2011-05-24 Lilly Co Eli agonistas peptìdicos seletivos do receptor vpac2
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
DK2321640T3 (en) * 2008-08-21 2017-02-27 Immunogenics Llc FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
TWI721976B (zh) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) * 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794217A (zh) * 2014-08-06 2017-05-31 血管生物科学 包含对患病组织具有选择性的药效团的组合物及其制备方法

Also Published As

Publication number Publication date
GT200300142A (es) 2004-03-17
HN2003000217A (es) 2004-07-26
MXPA04012305A (es) 2005-02-25
RU2005103396A (ru) 2005-09-20
US20090258826A1 (en) 2009-10-15
IL165499A (en) 2010-12-30
RU2360922C2 (ru) 2009-07-10
UY27893A1 (es) 2003-12-31
DOP2003000669A (es) 2004-01-31
EP1578358A2 (en) 2005-09-28
US20040058870A1 (en) 2004-03-25
ZA200501118B (en) 2006-08-30
IL165499A0 (en) 2006-01-15
PE20040677A1 (es) 2004-10-29
TW200409641A (en) 2004-06-16
AR040548A1 (es) 2005-04-13
CA2491279A1 (en) 2004-01-22
US7378494B2 (en) 2008-05-27
JP2006506969A (ja) 2006-03-02
WO2004006839A2 (en) 2004-01-22
AU2003267990A1 (en) 2004-02-02
PL377025A1 (pl) 2006-01-23
BR0312621A (pt) 2005-12-06

Similar Documents

Publication Publication Date Title
CN101405298A (zh) 垂体腺苷酸环化酶激活肽(pacap)受体(vpac2)激动剂及其药物使用方法
RU2269354C2 (ru) Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения
KR100892545B1 (ko) Ｐｙｙ 효능제 및 이의 용도
JP2008539735A (ja) グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
WO2006121904A1 (en) Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
US7507714B2 (en) Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
CN101001639A (zh) 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法
US6972319B1 (en) Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
US20090105122A1 (en) Selective neuropeptide y2 receptor agonists
US20090143283A1 (en) Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor (VPAC2) Agonists and Their Pharmacological Methods of Use
US20090280106A1 (en) Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
US6893844B1 (en) DNA encoding a new human hepatoma derived growth factor and producing method thereof
WO2006091505A2 (en) Neuropeptide y receptor agonists
CN1287171A (zh) 人神经元钙传感蛋白及其编码序列、以及制法和用途
HK1131161A (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
KR20050018988A (ko) 뇌하수체 아데닐레이트 사이클라제 활성화펩타이드(ｐａｃａｐ) 수용체(ｖｐａｃ２) 효능제 및 그의약물학적 사용방법
HK1109855A (en) Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
MXPA06008404A (en) Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
HK1073117B (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131161

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090408

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1131161

Country of ref document: HK